ClinicalTrials.gg
CompletedNCT01702298Updated Aug 24, 2018Results posted

A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)

A Phase 3 interventional study of Sitagliptin 100 mg/simvastatin 40 mg FDC and Metformin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2018-08-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
137th of 197
42 · median 102
Started
2012
with 15 others
Phase 3
74 of 198
none open now
Registered
124th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 137th largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is one of 74 in phase 3, and was the 124th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to examine the safety and tolerability of sitagliptin 100 mg/simvastatin 40 mg FDC (MK-0431D) in Vietnamese participants with type 2 diabetes mellitus with inadequate glycemic control on metformin.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has type 2 diabetes mellitus
  • Male, or female who is not of or if of reproductive potential agrees to abstain or use (or have their partner use) two acceptable methods of during the study and for 14 days after the last dose of study drug
  • Currently on metformin monotherapy (>=1000 mg per day) for at least 4 weeks prior to study participation
  • Not on statin therapy or other lipid-lowering agent for at least 6 weeks prior to study participation

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes mellitus or a history of ketoacidosis
  • History of 2 or more episodes of hypoglycemia resulting in seizure, coma or loss of consciousness over the past 3 months
  • On a thiazolidinedione (TZD) within the past 12 weeks
  • Has been treated with a statin or other lipid-lowering agent within 6 weeks prior to study participation
  • Is on or likely to require treatment with a prohibited medication (itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, protease inhibitors, nefazodone, gemfibrozil, cyclosporine, danazol, amiodarone, verapamil, diltiazem, amlodipine, ranolazine, niacin)
  • Intends to consume >1.2 liters of grapefruit juice per day during the study
  • Is on or likely to require treatment for >=2 consecutive weeks or repeated courses of (inhaled, nasal and topical corticosteroids are permitted)
  • Is on a weight loss program and not in the maintenance phase or has started a weight loss medication or has undergone bariatric surgery within 12 months prior to study participation
  • Has undergone a surgical procedure within 4 weeks of study participation or has planned major surgery during the study
  • History of myopathy or rhabdomyolysis with any statin
  • History of myocardial infarction, unstable or stable angina, angioplasty, bypass surgery, myocardial ischemia, peripheral artery disease, abdominal aortic aneurysm, , stroke of carotid origin or >50% obstruction of a carotid artery
  • Diagnosis of congestive heart failure with (NYHA) Class III or IV cardiac status
  • History of active liver disease (other than non-alcoholic steatosis) including chronic active or C, primary biliary cirrhosis, or symptomatic gallbladder disease
  • Chronic progressive neuromuscular disorder
  • Human immunodeficiency virus (HIV)
  • Hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
  • Currently being treated for hyperthyroidism or is on thyroid hormone replacement therapy and has not been on a stable dose for at least 6 weeks
  • History of \<=5 years prior to study participation, except for basal cell or squamous cell skin cancer or in situ cervical cancer
  • Positive urine pregnancy test
  • Pregnant or breastfeeding, or is expecting to conceive or donate eggs during the study, including 14 days following the last dose of study drug
  • User of recreational or illicit drugs or has had a recent history of drug abuse
  • Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in binge drinking
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Sitagliptin 100 mg/simvastatin 40 mg FDC

    Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin \>=1000 mg per day.

    Drug: Sitagliptin 100 mg/simvastatin 40 mg FDC · Drug: Metformin

Interventions

  • DrugSitagliptin 100 mg/simvastatin 40 mg FDC

    Drug page: Sitagliptin

    Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks

    Also known as: MK-0431D

  • Participants will continue pre-study dose of metformin tablet(s) \>=1000 per day

    Also known as: Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline in FPG at Week 6 based on longitudinal data analysis (LDA) model including both baseline and post-baseline measurements as response variable and term time.

    Time frame: Baseline and Week 6

  2. Percentage of Participants Who Experienced at Least One Adverse Event

    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.

    Time frame: Up to 8 weeks (including 14 days after final dose of study drug)

  3. Number of Participants Who Discontinued Study Drug Due to an Adverse Event

    Participants who were discontinued from study drug due to an adverse event during the 6 weeks of treatment.

    Time frame: Up to 6 weeks

Secondary outcomes

  1. Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

    Change from baseline in LDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.

    Time frame: Baseline and Week 6

  2. Change From Baseline in Total Cholesterol (TC)

    Change from baseline in TC was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.

    Time frame: Baseline and Week 6

  3. Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)

    Change from baseline in non-HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.

    Time frame: Baseline and Week 6

  4. Change From Baseline in Triglycerides (TG)

    Change from baseline in TG was measured as a percent change from baseline at Week 6 (median and distribution free 95% confidence interval).

    Time frame: Baseline and Week 6

  5. Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

    Change from baseline in HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.

    Time frame: Baseline and Week 6

07

Results

Posted May 30, 2014

Participant flow

Participant flow — Overall Study
MilestoneSitagliptin 100 mg/Simvastatin 40 mg FDC
Started42
Completed41
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline in FPG at Week 6 based on longitudinal data analysis (LDA) model including both baseline and post-baseline measurements as response variable and term time.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG)
mg/dLSitagliptin 100 mg/Simvastatin 40 mg FDC
Change From Baseline in Fasting Plasma Glucose (FPG)-27.6 ± 58.4
PrimaryPercentage of Participants Who Experienced at Least One Adverse Event

An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.

Time frame:
Up to 8 weeks (including 14 days after final dose of study drug)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced at Least One Adverse Event
Percentage of participantsSitagliptin 100 mg/Simvastatin 40 mg FDC
Percentage of Participants Who Experienced at Least One Adverse Event9.5 (2.7 to 22.6)
PrimaryNumber of Participants Who Discontinued Study Drug Due to an Adverse Event

Participants who were discontinued from study drug due to an adverse event during the 6 weeks of treatment.

Time frame:
Up to 6 weeks
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
ParticipantsSitagliptin 100 mg/Simvastatin 40 mg FDC
Number of Participants Who Discontinued Study Drug Due to an Adverse Event0
SecondaryChange From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

Change from baseline in LDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent change
Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Percent changeSitagliptin 100 mg/Simvastatin 40 mg FDC
Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)-46.5 ± 17.0
SecondaryChange From Baseline in Total Cholesterol (TC)

Change from baseline in TC was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent change
Change From Baseline in Total Cholesterol (TC)
Percent changeSitagliptin 100 mg/Simvastatin 40 mg FDC
Change From Baseline in Total Cholesterol (TC)-33.7 (-37.3 to -30.0)
SecondaryChange From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)

Change from baseline in non-HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent change
Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)
Percent changeSitagliptin 100 mg/Simvastatin 40 mg FDC
Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)-43.1 (-47.4 to -38.9)
SecondaryChange From Baseline in Triglycerides (TG)

Change from baseline in TG was measured as a percent change from baseline at Week 6 (median and distribution free 95% confidence interval).

Time frame:
Baseline and Week 6
Reported as:
Median · Percent change
Change From Baseline in Triglycerides (TG)
Percent changeSitagliptin 100 mg/Simvastatin 40 mg FDC
Change From Baseline in Triglycerides (TG)-31.8 ± 26.3
SecondaryChange From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

Change from baseline in HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent change
Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
Percent changeSitagliptin 100 mg/Simvastatin 40 mg FDC
Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)1.3 (-5.0 to 7.5)

Adverse events

Collected over Up to 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100 mg/Simvastatin 40 mg FDC—0/42 (0%)3/42 (7.1%)
Most frequent other events
Most frequent other events
EventSitagliptin 100 mg/Simvastatin 40 mg FDC
HypoglycemiaMetabolism and nutrition disorders3/42

Baseline characteristics

All participants enrolled

Age, Continuous
Age, Continuous(Years)Sitagliptin 100 mg/Simvastatin 40 mg FDC
Mean48.3 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 100 mg/Simvastatin 40 mg FDC
Female19
Male23
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mg/dL)Sitagliptin 100 mg/Simvastatin 40 mg FDC
Mean159.3 ± 40.9
Low-density lipoprotein cholesterol (LDL-C)
Low-density lipoprotein cholesterol (LDL-C)(mg/dL)Sitagliptin 100 mg/Simvastatin 40 mg FDC
Mean109.6 ± 27.2
Total Cholesterol (TC)
Total Cholesterol (TC)(md/dL)Sitagliptin 100 mg/Simvastatin 40 mg FDC
Mean195.2 ± 36.4
(Non-High-Density Lipoprotein Cholesterol (non-HDL-C)
(Non-High-Density Lipoprotein Cholesterol (non-HDL-C)(mg/dL)Sitagliptin 100 mg/Simvastatin 40 mg FDC
Mean152.0 ± 37.9
Triglycerides (TG)
Triglycerides (TG)(mg/dL)Sitagliptin 100 mg/Simvastatin 40 mg FDC
Mean225.3 ± 152.5
High-Density Lipoprotein Cholesterol (HDL-C)
High-Density Lipoprotein Cholesterol (HDL-C)(mg/dL)Sitagliptin 100 mg/Simvastatin 40 mg FDC
Mean43.1 ± 11.9
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in May 2013, 5 months.

Results were first posted in May 2014, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 5 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2012
First posted
Oct 8, 2012
StartActual
Dec 7, 2012
Primary completionActual
May 29, 2013
CompletionActual
May 29, 2013
Results first posted
May 30, 2014
Last update
Aug 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01702298
Responsible party
Sponsor
First posted
Oct 8, 2012
Start date
Dec 7, 2012
Primary completion
May 29, 2013
Completion
May 29, 2013
Results posted
May 30, 2014
Last update
Aug 24, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Metformin

Start the discussion